Liselotte Hyveled
Fortune : 34 236 $ au 31/05/2026
Fortune : 34 236 $ au 31/05/2026
Liselotte Hyveled is currently Director at RSP Systems A. Former positions include Non-Independent Director & Chief Patient Officer at Novo Nordisk A from 2022 to 2026, Independent Director at TriSalus Life Sciences, Inc. from 2024 to 2025, and Director at Novo Nordisk A from 2014 to 2018.
Education includes graduation from Copenhagen Business School in 2011 and from the University of Copenhagen in 1992.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/01/2025 | 10 040 ( 0,02% ) | 34 236 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
RSP Systems A/S
RSP Systems A/S Medical SpecialtiesHealth Technology Provides non-invasive solutions for sugar and insulin blood level measurements | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
| NOVO NORDISK A/S | Directeur/Membre du Conseil | 26/03/2026 |
| TRISALUS LIFE SCIENCES, INC. | Directeur/Membre du Conseil | 16/04/2025 |
| NOVO NORDISK A/S | Directeur/Membre du Conseil | 22/03/2018 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
RSP Systems A/S
RSP Systems A/S Medical SpecialtiesHealth Technology Provides non-invasive solutions for sugar and insulin blood level measurements | Health Technology |
TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. Medical SpecialtiesHealth Technology Engages in research, development and sales of innovative drug delivery technology & immune-oncology therapeutics | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national